US20060233894A1 - Anti-Inflammatory Humate Compositions and Methods of Use Thereof - Google Patents

Anti-Inflammatory Humate Compositions and Methods of Use Thereof Download PDF

Info

Publication number
US20060233894A1
US20060233894A1 US11/279,838 US27983806A US2006233894A1 US 20060233894 A1 US20060233894 A1 US 20060233894A1 US 27983806 A US27983806 A US 27983806A US 2006233894 A1 US2006233894 A1 US 2006233894A1
Authority
US
United States
Prior art keywords
humate
composition
anti
inflammatory
method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/279,838
Inventor
John Lown
Kevin Gill
Stephen Cutler
Horace Cutler
Stanley Pollock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TBNI Inc
Original Assignee
TBNI Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US10/336,484 priority Critical patent/US7067155B2/en
Application filed by TBNI Inc filed Critical TBNI Inc
Priority to US11/279,838 priority patent/US20060233894A1/en
Publication of US20060233894A1 publication Critical patent/US20060233894A1/en
Assigned to TBNI, INC. reassignment TBNI, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CUTLER, HORACE G., CUTLER, STEPHEN J., GILL, KEVIN, LOWN, JOHN F., POLLOCK, STANLEY H.
Application status is Abandoned legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/866Diabetes

Abstract

The disclosure relates to an anti-inflammatory composition containing humate, such as insoluble, granular, other insoluble, or soluble humate, particularly Menefee Humate®. The disclosure also includes other anti-inflammatory compositions containing humate and at least one additional anti-inflammatory agent such as indomethacin or another nonsteroidal anti-inflammatory drug. The disclosure includes a method of treating acute or chronic inflammation in an animal, including a human, by administering one of these compositions. A method of facilitating the therapeutic effect of a therapeutic drug in an animal by co-administering humate is also provided.

Description

    PRIORITY CLAIM
  • The present application is a continuation under 35 U.S.C. §120 of U.S. patent application Ser. No. 10/336,484, filed Jan. 3, 2003, titled “Anti-Inflammatory Humate Compositions and Methods of Use Thereof”, issued as U.S. Pat. No. ______ on ______.
  • FIELD OF THE INVENTION
  • The present invention relates to anti-inflammatory humate compositions and their methods of use. In particular, it relates to humate compositions containing natural humate and other anti-inflammatory chemicals. It additionally relates to the use of humate in treating inflammation either alone or in combination with other anti-inflammatory chemicals.
  • BACKGROUND OF THE INVENTION
  • Chemical studies of the composition of humates such as Menefee Humate® and leonardite have revealed that they are mainly composed of the mixed salts of acid radicals found in soil humus, a product of the decay of organic matter that contains both humic and nonhumic material. Such acid radicals are collectively termed “humic acids”, having individual factions named humin, humic acid, ulmic acid and fulvic acid.
  • Humic acids, defined as the portion of soil humus that is soluble in alkaline solution, but insoluble in acid solution, are a form of organic matter that often is added to the soil to increase fertility. Humic acids are found in rotting vegetable matter and can be detected in the black slime of an ordinary compost pit in a home garden. They are also found in the brown organic matter of a variety of soils, as well as in peats, manure, lignite, leonardite, brown coals, and the Menefee Humate®.
  • The exact structure of the humic acids is unknown. However, humic acids appear to be associations of molecules forming aggregates of elongated bundles of fibers at low pH, and open flexible structures perforated by voids at high pH. These voids, of varying dimensions, trap organic or inorganic particles of appropriate electronic charge. Humic acids do not have a single unique structure, but are a mixture of intermediate chemical products resulting from the decomposition and conversion of lignin and other plant materials to hard coal. Humic acids apparently are formed by the bacterial and chemical degradation of plant tissue, but in soils they also may be formed by certain secondary processes such as polymerization of polyphenols leached by rain from surface leaf litter, and condensation of phenols, quinones, and proteins that are provided by the action of soil micro-organisms and small animals on soil carbohydrates. As a result, humic acids are best characterized in terms of their origin and soil environment, rather than in rigid terms of chemical composition or chemical properties.
  • The humic acids have a large cation exchange capacity and hold multivalent metallic elements, such as micronutrient elements, very strongly. The molecular weight of the humic acids range from 800 to 500,000, with the weight average molecular weight ranging from about 5,000 to about 50,000. The cation exchange capacity of the humic acids varies from about 200 to about 600 meq CaCO2 per 100 grams at pH 7, depending upon the origin of the extracted acids. Humic acids are polyelectrolytes and are believed to form complexes with clay particles thus enabling humic acids to bind multivalent elements with great tenacity. When the cation exchange sites on the humic acid molecule are filled predominantly with hydrogen ions, the material, considered to be an acid, is insoluble in water. However, when the predominant cations at the exchange sites are other than hydrogen, the material is called a “humate.” Humates of monovalent alkali metals or ammonia are soluble in water. Such humates are referred to as “soluble”. The humates of most multivalent metals are insoluble in water. Such humates are referred to as “insoluble”. The term “humate” as used herein refers to both humate as well as the humic acids found in humate.
  • Humate has been used for decades as plant fertilizer and as an animal food supplement because of its general ability to produce healthier animals. More recently it has been used as a dietary supplement (See U.S. Pat. No. 5,626,881.) A variety of studies have explored it effects in animals. For example, humic acids' capacity to increase uptake of iron when administered as a humic acid/iron chelate was studied by Fuchs and Kunhert (Dtsch. tierarzti, 97(5): 208-9 (1990)). Low molecular weight humic acids have been found to be effective at crossing mitochondrial membranes (Viser, S.A. , The Science of the Total Environment, 62: 347-354 (1987)). Humic acids have also been shown to to absorb mutagenic chemicals and prevent their disruptive effects in bacteria (Sato, T., et al., Mutation Research, 162: 173-178 (1986); Sate, T., et al., Mutation Research, 176: 199-204 (1987)).
  • The effects of humate or humic acids on immune system function have also been studied. Overall, humic acids and humate have been found to stimulate immune cells or the immune response. (See Gau, R.J., et al., Toxicol. Appl. Pharmacol. 166(1): 59-67 (2001); Lange, N., et al., Arch. Exper. Vet. Med., 2: 140-6 (1987); Reide, U.N., et al., Virchows Archir. B. Cell Pathol., 60: 27-34 (1991); and Kuhnert et al., Dtsch. tierarztl. 96(1): 3-10 (1989).) Thus it came as some surprise when Ye et al. (Ye, S.B., et al., Acta Acad. Med. Sichuan 2: 127-9 (1985)) reported that intraperitoneal injection of Hong Yuan peat-derived sodium humate reduced swelling of inflamed rat paws.
  • Although it is not impossible for an immune-stimulatory agent to reduce inflammation, which is partially due to immune response, agents with these properties in combination are not common. Unfortunately, direct intraperitoneal injection of large amounts of humate as described in Ye et al. is not practical for non-experimental purposes. For example, Ye et al. injected 50 mg/kg of soluble sodium humate; an equivalent amount for an adult human weighing 100 kg would be 5 g of humate. Even if the humate were solubilized in a very concentrated solution, this would require injection of an uncomfortably large volume of liquid. Additionally, although humate is generally beneficial, overly large amounts of it are actually less effective as an anti-inflammatory agent than smaller amounts and may cause other, unknown health problems.
  • Inflammation is signaled by redness, swelling, heat, and pain as a reaction of the body against injury or assault. A variety of chemicals have been implicated as chemical mediators of the inflammatory reaction, including histamine, serotonin, kinins, prostaglandins, platelet-activating factors, leukotrienes, and, from nerve endings, substance P. Mediators of the acute inflammatory reaction seem to play roles in one or more of increasing vascular permeability, attracting leukocytes, producing pain, local edema, and necrosis.
  • There are steroid and non-steroid, anti-inflammatory drugs known to the art. U.S. Pat. No. 4,579,844, inventors Rovee et al., issued Apr. 1, 1986, discloses topically treating an inflammatory condition of the skin by use of the prostaglandin synthetase inhibitor concurrently with a corticosteroid. U.S. Pat. No. 4,404,198, inventor Kelley, issued Sep. 13, 1983, discloses the topical application of a composition including phenyl salicylate to treat inflammation. U.S. Pat. No. 3,980,778, inventors Ayer et al., issued Sep. 14, 1976, discloses asteroid for use in the topical, oral or parenteral treatment of skin and mucous membrane inflammations. Numerous other anti-inflammatory medications, ranging from aspirin, acetaminophen and ibuprofen to newer COX-2 inhibitors and ketoprofin.
  • The wide variety of anti-inflammatory drugs is indicative of the fact that not all drugs are suitable for every indication or each individual patient. Despite this variety, there are still a number of patients whose needs are not well-met by the available range of anti-inflammatory drugs when administered in customary fashions.
  • SUMMARY OF THE INVENTION
  • The present invention provides a novel anti-inflammatory composition including humate as well as another composition including humate with at least one other anti-inflammatory chemical. The anti-inflammatory compositions may be for oral, topical or injection administration to an animal, including a human. In an exemplary embodiment, the humate is prehistoric humate such as Menefee Humate® derived from the Menefee Geological Formation in N. Mex. Additionally, in an exemplary embodiment the humate comprises at least 50% humic acids.
  • When the mode of administration is oral or topical, the humate may be insoluble, granular humate, other insoluble humate, or soluble humate. When the mode of administration is by injection, the humate is preferably soluble. In an exemplary embodiment, the humate comprises between approximately 0.1% and 1.0% and, more specifically, approximately 0.5% by weight of the composition. Alternatively, the humate composition may be administered orally in such a way that between approximately 0.1% and 1.0% and, more specifically, approximately 0.5% by weight of the animal's total food intake is humate.
  • The humate composition may also contain at least one additional anti-inflammatory agent. In an exemplary embodiment, this second agent is a nonsteroidal anti-inflammatory drug. For example, it may be an indole derivative such as indomethacin.
  • The invention also includes a method of reducing inflammation in a tissue of an animal, including a human, by supplying a composition containing humate to the tissue through oral, topical or injection administration. In an exemplary embodiment, if the humate is supplied orally it may constitute approximately 0.1% and 1.0% and, more specifically, approximately 0.5% by weight of the total food consumed by the animal.
  • The method may also include the additional step of supplying a second anti-inflammatory agent to the tissue of an animal, including a human, through oral, topical or injection administration. In an exemplary embodiment, the dosage of the second anti-inflammatory agent is reduced as compared with the dosage that would be administered if no composition containing humate were administered. The second anti-inflammatory agent may be supplied in the composition containing humate or it may be supplied in a separate composition from that containing humate. If the second agent is supplied separately from the humate it may be supplied approximately contemporaneously with the composition containing humate using the same type of administration. In a further exemplary embodiment, the humate acts a carrier to facilitate transport of the second anti-inflammatory agent to the tissue or cell where it exerts its activity. In another exemplary embodiment, a synergistic effect between the humate and other anti-inflammatory agent occurs.
  • In an exemplary embodiment, the composition containing humate is supplied orally in such a manner that humate constitutes approximately 0.1% and 1.0% and, more specifically, approximately 0.5% by weight of the animal's food intake and the second anti-inflammatory composition is indomethacin administered in the amount of approximately 3 mg/kg animal. The inflammation may be acute or chronic. One example of chronic inflammation is arthritis.
  • The invention additionally includes a method of increasing the therapeutic effect in an animal, including a human, of a therapeutic chemical by administering the therapeutic chemical with humate. The administration of humate may be contemporaneous and in the same manner as the administration of the therapeutic chemical, such as when they are in a single composition.
  • In an exemplary embodiment, the humate serves as a carrier for the therapeutic chemical and facilitates its delivery to a tissue or cell of the animal where the therapeutic chemical exerts its therapeutic effect. The humate and therapeutic chemical may be administered orally, topically or by injection.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.
  • FIG. 1 depicts the inhibitory effects of orally administered insoluble, granular Menefee Humate® on carrageenan-induced edema in rats. Percent inhibition reflects inhibition of swelling in an edemic paw as compared to a non-edemic paw. Solution percentages represent weight percentage of humate in powder suspension with feed mix.
  • FIG. 2 depicts the inhibitory effects of orally administered insoluble, granular Menefee Humate®, indomethacin, and Menefee Humate® plus indomethacin on carrageenan-induced edema in rats. Percent inhibition reflects swelling in an edemic paw as compared to a non-edemic paw. Solution percentages represent weight percentage of humate in powder suspension with feed mix.
  • FIG. 3 depicts the anti-inflammatory effects of orally administered insoluble, granular Menefee Humate® on adjuvant-induced arthritis in rats. All results are from rats which had received humate for 15 days. Solution percentages represent weight percentage of humate in powder suspension with feed mix. FIG. 3 a depicts the effect of Menefee Humate® on % change in arthrogram score after 15 days of humate administration. FIG. 3 b depicts the % change effect of Menefee Humate® on right hind paw volume after 15 days of administration. FIG. 3 c depicts the % change effect of Menefee Humate® on left hind paw volume after 15 days of administration.
  • FIG. 4 depicts the anti-inflammatory effects of orally administered insoluble, granular Menefee Humate® on adjuvant-induced arthritis in rats. All results are from rats which had received humate for 21 days. Solution percentages represent weight percentage of humate in powder suspension with feed mix. FIG. 4 a depicts the effect of Menefee Humate® on arthrogram score after 21 days of humate administration. FIG. 4 b depicts the effect of Menefee Humate® on right hind paw volume in mm of Hg displaced after 21 days of administration. FIG. 4 c depicts the effect of Menefee Humate® on left hind paw volume in mm Hg displaced after 21 days of administration.
  • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention relates to anti-inflammatory compositions including humate, which may also contain or be co-administered with at least one other anti-inflammatory agent. The invention also includes methods of administering such compositions to animals, including humans, with inflammation.
  • The humate may be administered in a soluble form or in a granular, insoluble form or in other forms. In an exemplary embodiment, granular, insoluble or soluble Menefee Humate® is used. The mode of administration will depend upon the form of humate, with soluble humate preferred for intravenous(IV), intramuscular(IM) or other types of injection. Soluble humate may also be used for oral ingestion or topical application, however, insoluble, granular humate or other insoluble humate is also suitable for these purposes. The humate may be administered to an area of inflammation through injection or in topical applications. Orally administered humate may be suitable to treat inflammation anywhere in the body.
  • Humate may also be combined with at least one other anti-inflammatory agent. Such combination may be effected by preparing a composition containing both humate and at least one other anti-inflammatory agent or by co-administering separate compositions, for example, one containing humate and another or others containing at least one other anti-inflammatory agent. In an exemplary embodiment, if the humate and anti-inflammatory agent or agents are in separate compositions, administration is approximately contemporaneous. In another embodiment, humate is administered on a regular basis, such as daily, while the anti-inflammatory agent or agents are administered periodically, for example to treat or prevent increased inflammation.
  • All compositions of the present invention may be prepared in a pharmaceutically acceptable carrier. Different carriers may be required depending upon the solubility of the humate selected. The selection of an appropriate carrier will be apparent to one skilled in the art. It is known in the art that pH of the solution affects the solubility of humate and its constituent parts, such as certain humic acids.
  • The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.
  • EXAMPLES Example 1-Composition of Menefee Humate®
  • Menefee Humate® is a humate of prehistoric origin found in the Menefee Geological Formation of northern N. Mex. Humate differs in its chemical and physical properties depending upon the source. Menefee Humate® is one of the world's highest quality humates for other known uses. Therefore, it was selected for use in the examples that follow.
  • Insoluble, granular Menefee Humate® is prepared by mining then screening the humate to a desired granule size. Because this process does not chemically alter the humate, it remains insoluble. The pH of the insoluble, granular Menefee Humate® is approximately 3.4 and its composition is approximately as follows: Humic Acids 50.00%  Nitrogen (N) 1.00% Potassium (K2O) <0.10%   Phosphate (P2O5) <0.10%   Calcium (Ca) 1.04% Sulfur (S) 0.18% Magnesium (Mg) 0.14% Iron (Fe) 0.30% Manganese (Mn) 0.0004%  Copper (Cu) 0.0002% 
  • Other trace minerals may also be present in some samples.
  • Soluble Menefee Humate® is prepared by forming a solution of granular humate with water, potassium phosphate and a wetting agent. The solution is then screened and processed through a spray-dryer to obtain a water-soluble powder. This powder may be added to water to form a solution with a desired concentration. The pH of soluble Menefee Humate® is approximately 6.2 and its composition is approximately as follows: Humic Acids 60.0% Fulvic Acid 26.0% Carbon 11.5% Calcium (Ca)  1.7% Sulfur (S)  0.4% Magnesium (Mg)  0.3% Iron (Fe) 0.06%
  • Other trace minerals may also be present in some samples.
  • Example 2-Effects of Humate on Acute Inflammatory Response
  • Male Sprague Dawley rats weighing approximately 50 g were purchased from Harlan U.S. and housed in wire cages in the animal facility at Mercer University School of Pharmacy. The animals were given a short period of time to acclimate to the new environment and received powdered rat chow from Purina and water ad libitum. At the beginning of the experimental period, insoluble, granular Menefee Humate® was mixed with the powdered rat chow and placed in feeders. Rats received chow with either 0.1%, 0.5% or 1.0% insoluble, granular Menefee Humate® by weight. After 54 days of receiving humate in their food, the animals were injected in the subplantar region of the left hind paw with carrageenan (2%; 0.5 mg in 0.05 ml of saline). This substance produces an acute inflammation in the infected paw that increases over time and reaches a maximum approximately three hours post-injection. The contralateral paw received only saline and served as the negative control.
  • The paw volumes were measured plethysmographically by displacement of mercury three hours post-injection of the carrageenan. The volume of the negative control paw was subtracted from the volume of the carrageenan-injected paw to determine the degree of inflammation present. The average volume of edema obtained from the Menefee Humate®-treated animals was divided by the average volume of edema from the control animals (carageenan only, no humate) and the quotient (multiplied by 100) subtracted from 100 to obtain the percent inhibition of edema produced by Menefee Humate®.
  • The effect of insoluble, granular Menefee Humate® on carrageenan-induced edema is shown in FIG. 1. The 0.1% and the 0.5% concentrations of humate produced a similar and statistically significant inhibition of hind paw inflammation. The inhibition was approximately 27% (P<0.05). The higher concentration of humate did not affect the inflammatory process.
  • In the 0.1% group, there was one animal whose response to inflammation did not appear to be typical of animals of that group. If that animal is eliminated from the results, there was actually a 48% inhibition of carrageenan-induced edema. Therefore, it appears that at certain concentrations beginning at approximately 0.1% by weight of food, orally administered insoluble, granular Menefee Humate® inhibits acute inflammation. This effect does not persist however, at higher concentrations of humate, beginning at approximately 1.0% by weight of food.
  • Example 3-Effect of Insoluble, Granular Menefee Humate® on Anti-Inflammatory Activity of Indomethacin
  • Male Sprague Dawley rats weighing approximately 50 g were purchased from Harlan U.S. and housed in wire cages in the animal facility at Mercer University School of Pharmacy. The animals were given a short period of time to acclimate to the new environment and received powdered rat chow from Purina and water ad libitum. At the beginning of the experimental period, the rats were divided into six groups of eight each. Control and indomethacin only groups received only powdered rat chow for the entire length of the experiment. For the four other groups, insoluble granular Menefee Humate® was mixed with the powdered rat chow and placed in feeders. Rats received chow with either 0.1%, 0.5% or 1.0% insoluble, granular Menefee Humate® by weight. After 37 days of receiving humate in their food, the animals weighed approximately 278 g, which in an appropriate size for inducing inflammation. An amount of indomethacin sufficient to achieve 50% inhibition of carrageenan-induced edema (3mg/kg) was administered to the indomethacin only group and to the 0.1% humate plus indomethacin group. The indomethacin was administered subcutaneously 30 minutes before the administration of carageenan. The rats were then injected in one hind paw with carrageenan (2%). After three hours, the hind paws were measured by mercury displacement.
  • The results of this experiment are shown in FIG. 2. As in Example 2, the animals receiving 0.1% or 0.5% humate exhibited significant inhibition of inflammation (approximately 30%, P<0.05). That receiving only 0.05% humate exhibited only around a 10% inhibition of inflammation, indicating that this dose was too low to have a significant effect on carrageenan-induced edema. Those animals receiving only indomethacin exhibited around a 50% inhibition of edema, as expected (P<0.05).
  • Surprisingly, the animals that received both indomethacin and 0.1% concentration of humate exhibited a 66.8% inhibition of carrageenan-induced edema (P<0.05). This represents a 28% increase in the anti-inflammatory activity as compared to indomethacin alone. These results suggest that a combination of indomethacin or another anti-inflammatory agent with insoluble, granular Menefee Humate® or another humate may allow the administration of lower amounts of the non-humate anti-inflammatory compound. Given the toxicity and side-effects of many known anti-inflammatory compounds (which are much more dangerous or discomforting than any known side-effects of humate), this capacity to lower the dose of such compounds required to treat inflammation may greatly benefit both human and animal patients.
  • The basis for this increase in the effectiveness of indomethacin may be due to a synergistic combination of the anti-inflammatory effects of humate and those of indomethacin. However, given the tendency of humate to bind to other molecules and transport them across lipid membranes, it is also possible that the humate serves as a carrier of the indomethacin, allowing it to reach target areas more readily.
  • Example 4-Effects of Menefee Humate® on Chronic, Immunologically-Induced Inflammatory Response
  • Male Sprague Dawley rats weighing approximately 50 g were purchased from Harlan U.S. and housed in wire cages in the animal facility at Mercer University School of Pharmacy. The animals were given a short period of time to acclimate to the new environment and received powdered rat chow from Purina and water ad libitum. At the beginning of the experimental period, the rats were divided into six groups of eight each. Negative and positive control groups received only powdered rat chow for the entire length of the experiment. For the four other groups, insoluble, granular Menefee Humate® was mixed with the powdered rat chow and placed in feeders. Rats received chow with either 0.1%, 0.5% or 1.0% insoluble, granular Menefee Humate® by weight. All rats remained on their assigned diets for 17 days prior to mycobacterium administration and for 21 days after the administration.
  • When the animals reached a body weight known to allow the greatest amount of inflammation (around 180 g), a heat-killed and dried Mycobacterium butyricum (10 mg) suspended in light mineral oil was injected into the base of the tail of all animals except the negative control animals. The negative control group received an injection of mineral oil only.
  • The Mycobacterium Wax D fraction induces a cellular immune response with the first signs of inflammation appearing approximately 12 to 15 days post-injection. At that time, an inflammatory response was observed in all but the negative control animals. The inflammatory response occurred in both hind paws, both fore paws and the ears of the animals. The inflammation of the hind paws as measured plesthmographically by displacement of mercury was measured at 15 and 21 days post-injection. The degree of inflammation in the forepaws and ears as well as the degree of hind paw ankylosis was determined using a grading system know to the art as the arthrogram score.
  • The effect of insoluble, granular Menefee Humate® on arthritis in rats 15 days after injection is shown in FIG. 3 a, b and c. The effects of humate on inflammation 21 days after injection are shown in FIG. 4 a, b and c. Arthrogram scores were obtained by visually grading the following: fore paws, redness and swelling; ear, redness and/or nodular lesions; hind paws, ankylosis; and tail, ankylosis and/or nodules. The scoring system ranged from 0 to 2+, where 0 indicates no indications, 1+ indicates moderate indications and 2+ indicates severe indications. A maximal score of 18 could this be obtained. The average score obtained by the drug-treated group was divided by the average score obtained by the arthritic control group time 100. This number was subtracted from 100 to obtain the percent inhibition caused by the Menefee Humate®.
  • To obtain the percent inhibition of adjuvant arthritis produced by the Menefee Humate®, the following calculations were made: the average hind paw volume obtained for each paw of the negative control animals (no adjuvant, only mineral oil) was subtracted from the average hind paw volume obtained for each paw of the positive control animals (animals received mycobacterium). This volume represents the true inflammation produced in the controls. The same procedure was performed on the Menefee Humate®-treated animals to obtain the inflammation produced in these animals. The effect of the inflammation produced by the Menefee Humate® was then obtained by dividing the inflammation obtained in the Menefee Humate®-treated group by the inflammation obtained in the positive control group times 100. The number was then subtracted from 100 to obtain the % inhibition produced by the Menefee Humate®.
  • The 0.5% concentration of the insoluble, granular Menefee Humate® produced a statistically significant inhibition of the arthrogram score (FIG. 3 a) and right hind paw swelling (FIG. 3 b) on the 15th day after Mycobacterium injection (P<0.05 for 0.5% concentration in both). Although some inhibition was also seen in the left paw, it was not statically significant (FIG. 3 c). The 0.05%, 0.1% and 1% concentrations of humate did not produce a significant inhibitory effect on either the arthrogram score or swelling in the left or right hind paw. When the effects of insoluble, granular Menefee Humate® on chronic inflammation were evaluated again at 21 days post-injection so statistically significant inhibition of inflammation was seen.
  • This suggests that Menefee Humate®, when ingested orally at a concentration of approximately 0.5% by food weight prior to and during onset of chronic inflammation, has an inhibitory effect on chronic inflammation. However, such inhibitory effect is not maintained for the long-term. Nevertheless, these results indicate that humate may serve a purpose in delaying the onset of debilitating effects of chronic inflammatory diseases, such as arthritis. Humate may also present a viable alternative to stronger medications that may have harmful side effects during the early stages of some chronic inflammations.
  • All of the compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims

Claims (22)

1. An anti-inflammatory composition comprising:
humate as a primary anti-inflammatory agent; and
a pharmaceutically acceptable carrier.
2. The composition of claim 1, wherein the humate is prehistoric humate.
3. The composition of claim 2, wherein the humate is derived from the Menefee Geological Formation in N. Mex.
4. The composition of claim 1, wherein the humate comprises at least 50% humic acids.
5. The composition of claim 1, wherein the composition is for oral or topical administration and the humate is insoluble, granular humate.
6. The composition of claim 1, wherein the composition is for injection administration and the humate is soluble.
7. The composition of claim 1, wherein the humate comprises between approximately 0.1% and 1.0% by weight of the composition.
8. The composition of claim 7, wherein the humate comprises approximately 0.1- 0.5% by weight of the composition.
9. The composition of claim 1, wherein humate constitutes the sole anti-inflammatory agent.
10. The composition of claim 9, wherein at least one additional anti-inflammatory agent is a nonsteroidal anti-inflammatory drug.
11. The composition of claim 10, wherein the nonsteroidal anti-inflammatory drug is an indole derivative.
12. The composition of claim 11, wherein the nonsteroidal anti-inflammatory drug is indomethacin.
13. A method of reducing inflammation in a tissue of an animal comprising supplying a composition containing humate as a primary anti-inflammatory agent to the tissue through oral, topical or injection administration.
14. The method of claim 13, wherein the humate is supplied orally and constitutes approximately 0.1 to 0.5% by weight of the total food consumed by the animal.
15. The method of claim 13, wherein the method comprises supplying a composition containing humate as the sole anti-inflammatory agent.
16-20. (canceled)
21. The method of claim 13, wherein the composition containing humate is supplied orally and wherein the humate constitutes approximately 0.1- 0.5% by weight of the animal's food intake
22. The method of claim 13, wherein the animal is a human.
23. The method of claim 13, wherein the inflammation is acute.
24. The method of claim 13, wherein the inflammation is chronic.
25. The method of claim 24, wherein the inflammation is a result of arthritis.
26-31. (canceled)
US11/279,838 2003-01-03 2006-04-14 Anti-Inflammatory Humate Compositions and Methods of Use Thereof Abandoned US20060233894A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/336,484 US7067155B2 (en) 2003-01-03 2003-01-03 Anti-inflammatory humate compositions and methods of use thereof
US11/279,838 US20060233894A1 (en) 2003-01-03 2006-04-14 Anti-Inflammatory Humate Compositions and Methods of Use Thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/279,838 US20060233894A1 (en) 2003-01-03 2006-04-14 Anti-Inflammatory Humate Compositions and Methods of Use Thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/336,484 Continuation US7067155B2 (en) 2003-01-03 2003-01-03 Anti-inflammatory humate compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
US20060233894A1 true US20060233894A1 (en) 2006-10-19

Family

ID=32681023

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/336,484 Active US7067155B2 (en) 2003-01-03 2003-01-03 Anti-inflammatory humate compositions and methods of use thereof
US11/279,838 Abandoned US20060233894A1 (en) 2003-01-03 2006-04-14 Anti-Inflammatory Humate Compositions and Methods of Use Thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/336,484 Active US7067155B2 (en) 2003-01-03 2003-01-03 Anti-inflammatory humate compositions and methods of use thereof

Country Status (1)

Country Link
US (2) US7067155B2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067155B2 (en) * 2003-01-03 2006-06-27 Tbni, Inc. Anti-inflammatory humate compositions and methods of use thereof
TR201003579A2 (en) 2010-05-06 2010-07-21 Dizman Mümin Lower and upper topical and injectable wound treatment agent to improve the skin diseases.
US10259754B2 (en) * 2016-11-21 2019-04-16 AG Export International, LLC Soluble humin

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980778A (en) * 1973-10-25 1976-09-14 The Upjohn Company Anti-inflammatory steroid
US4404198A (en) * 1979-01-24 1983-09-13 Beecham Inc. Phenyl Salicylate as a topical anti-inflammatory
US4579844A (en) * 1976-05-13 1986-04-01 Johnson & Johnson Topical anti-inflammatory drug therapy
US5456935A (en) * 1993-11-27 1995-10-10 Rutgerswerke Ag Food products
US5466824A (en) * 1989-05-22 1995-11-14 Biochemical Veterinary Research Pty. Ltd. Divalent metal complexes of indomethacin, compositions and medical methods of use thereof
US5626881A (en) * 1995-05-16 1997-05-06 Menefee Mining Corporation Humate dietary supplement
US6410588B1 (en) * 1998-04-14 2002-06-25 The Mathilda And Terence Kennedy Institute Of Rheumatology Use of cannabinoids as anti-inflammatory agents
US7067155B2 (en) * 2003-01-03 2006-06-27 Tbni, Inc. Anti-inflammatory humate compositions and methods of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US362190A (en) * 1887-05-03 stewart
US4141425A (en) * 1976-08-04 1979-02-27 L. L. Payne Means for generating electrical energy for vehicle
US4168759A (en) * 1977-10-06 1979-09-25 Hull R Dell Automobile with wind driven generator
US4418287A (en) * 1978-10-10 1983-11-29 Power Group International Corporation Wind power generator and control therefore
US4254843A (en) * 1979-07-20 1981-03-10 Han Joon H Electrically powered vehicle
US4423368A (en) * 1980-11-17 1983-12-27 Bussiere Jean L Turbine air battery charger & power unit
US5584355A (en) * 1992-10-14 1996-12-17 Burns; David J. Electrical vehicle
US5280827A (en) * 1992-12-22 1994-01-25 Cletus L. Taylor Venturi effect charging system for automobile batteries
US5386146A (en) * 1993-04-22 1995-01-31 Hickey; John J. In-line auger driven charging system
US5680032A (en) * 1995-12-19 1997-10-21 Spinmotor, Inc. Wind-powered battery charging system
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6138781A (en) * 1997-08-13 2000-10-31 Hakala; James R. System for generating electricity in a vehicle
US5986429A (en) * 1998-06-29 1999-11-16 Mula, Jr.; John Battery charging system for electric vehicles

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980778A (en) * 1973-10-25 1976-09-14 The Upjohn Company Anti-inflammatory steroid
US4579844A (en) * 1976-05-13 1986-04-01 Johnson & Johnson Topical anti-inflammatory drug therapy
US4404198A (en) * 1979-01-24 1983-09-13 Beecham Inc. Phenyl Salicylate as a topical anti-inflammatory
US5466824A (en) * 1989-05-22 1995-11-14 Biochemical Veterinary Research Pty. Ltd. Divalent metal complexes of indomethacin, compositions and medical methods of use thereof
US5456935A (en) * 1993-11-27 1995-10-10 Rutgerswerke Ag Food products
US5626881A (en) * 1995-05-16 1997-05-06 Menefee Mining Corporation Humate dietary supplement
US6410588B1 (en) * 1998-04-14 2002-06-25 The Mathilda And Terence Kennedy Institute Of Rheumatology Use of cannabinoids as anti-inflammatory agents
US7067155B2 (en) * 2003-01-03 2006-06-27 Tbni, Inc. Anti-inflammatory humate compositions and methods of use thereof

Also Published As

Publication number Publication date
US20040131705A1 (en) 2004-07-08
US7067155B2 (en) 2006-06-27

Similar Documents

Publication Publication Date Title
Ganther et al. Selenium metabolism: II. Modifying effects of sulfate
Ozols et al. High-dose cisplatin in hypertonic saline
Handy Dietary exposure to toxic metals in fish
JP2572768B2 (en) Pas as an active ingredient levodopa methyl ester - Parkinson&#39;s Disease agent
US6090414A (en) Method and composition to reduce cancer incidence
Daly et al. Effects of intravenous nutrition on tumor growth and host immunocompetence in malnourished animals
Selvam et al. Effect of A. lanata leaf extract and Vediuppu chunnam on the urinary risk factors of calcium oxalate urolithiasis during experimental hyperoxaluria
Goyal et al. Asparagus racemosus-An update
US3966908A (en) Method of treating degenerative joint afflictions
JP2528115B2 (en) Inoshito - Rutorihosufue - pharmaceutical compositions containing bets
US4871528A (en) Pharmaceutical compositions having antineoplastic activity
Goodman Therapeutic effects of organic germanium
US5008248A (en) Veterinary compositions for the treatment of scours and dehydration
Dunkelberg Carcinogenicity of ethylene oxide and 1, 2-propylene oxide upon intragastric administration to rats
CA1134275A (en) Amino acid solutions for patients with cancers
Sorenson et al. Treatment of rheumatoid and degenerative diseases with copper complexes
Ross et al. Cycloaliphatic Amino Acids in Cancer Chemotherspy
Goldberg et al. Destruction of pancreatic acinar tissue by DL-ethionine.
Pletscher et al. Antagonism between harmaline and long-acting monoamine oxidase inhibitors concerning the effect on 5-hydroxytryptamine and norepinephrine metabolism in the brain
Luo et al. Inhibitory effects of molybdenum on esophageal and forestomach carcinogenesis in rats
Manitius et al. Some observations on the influence of a magnesium-deficient diet on rats, with special reference to renal concentrating ability
Sutter et al. Histamine liberation by codeine and polymyxin B in urticaria pigmentosa
Waldron-Edward et al. Studies on the Inhibition of Intestinal Absorption of Radioactive Strontium: III. The Effect of Administration of Sodium Alginate in Food and in Drinking Water
Andersson Inhibitory effects of hydrochloric acid in antrum and duodenum on gastric secretory responses to test meal in Pavlov and Heidenhain pouch dogs
Menon et al. Effect of isoflayones genistein and daidzein in the inhibition of lung metastasis in mice induced by B16F‐10 melanoma cells

Legal Events

Date Code Title Description
AS Assignment

Owner name: TBNI, INC., TEXAS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LOWN, JOHN F.;GILL, KEVIN;CUTLER, STEPHEN J.;AND OTHERS;REEL/FRAME:019900/0478;SIGNING DATES FROM 20030127 TO 20030204

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION